Prestige Consumer Healthcare PBH Cough & Cold — Total revenues

Other product segments

Similar metrics at other companies

SUPNGOCOVRI — Total revenues

$35.24M+14.8%

OMCLConsumables — Total revenues

$26.14M+4.2%

OGNOther Respiratory — Revenue

$12M-7.7%

MRNACOVID — Total Revenue

$345M+311%

VRTXTotal CF product revenues, net — Total revenues

$2.92B+6.2%

CONConsumer health — Revenue

$7.83M-9.1%

Questions, answered.

What is Prestige Consumer Healthcare's cough & cold — total revenues?

Prestige Consumer Healthcare (PBH) reported cough & cold — total revenues of $26.29M in Q1 2026.

How has Prestige Consumer Healthcare's cough & cold — total revenues changed year-over-year?

Prestige Consumer Healthcare's cough & cold — total revenues decreased by 2.3% year-over-year, from $26.91M to $26.29M.

What is the long-term trend for Prestige Consumer Healthcare's cough & cold — total revenues?

Over 4 years (2022 to 2026), Prestige Consumer Healthcare's cough & cold — total revenues has grown at a -1.2% compound annual growth rate (CAGR), from $107.08M to $101.91M.

What does cough & cold — total revenues mean?

This metric represents the total gross sales generated from the company's Cough and Cold product portfolio, which includes over-the-counter treatments for respiratory and seasonal ailments. It serves as a key indicator of the segment's market demand, brand strength, and ability to capture consumer spending within the niche healthcare category. Tracking these revenues helps investors assess the performance and growth trajectory of the company's specific therapeutic offerings relative to broader consumer health market trends.